Skip to content

A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02781311
Enrollment
169
Registered
2016-05-24
Start date
2016-07-14
Completion date
2018-05-22
Last updated
2019-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alopecia

Brief summary

This study will evaluate the safety, tolerability and efficacy of the oral administration of setipiprant tablets 1000 mg twice daily (BID) relative to placebo in 18 to 49 years old males with androgenetic alopecia (AGA).

Interventions

Setipiprant tablets, orally, BID for 24 weeks.

DRUGPlacebo

Placebo tablets, orally, BID for 24 weeks.

DRUGFinasteride

Finasteride tablet, orally, once daily for 24 weeks.

Sponsors

Allergan
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
18 Years to 49 Years
Healthy volunteers
No

Inclusion criteria

* Participant has androgenetic alopecia (AGA) * Participant agrees to maintain current hair care regimen, refraining from hair weaving, hair colorants or dyes and non-study hair growth products during the study.

Exclusion criteria

* History of hair loss for reasons other than AGA * Scarring of the scalp or any condition or disease of the scalp, hair or hair shaft * Use of products within 6 months of study start used continuously for at least 1 month that could impact hair growth * Hair-weaving within 6 months * Use of hair colorants or dyes within 6 months.

Design outcomes

Primary

MeasureTime frameDescription
Change From Baseline in Target Area Hair Count (TAHC) at Week 24Baseline (Day 1) to Week 24TAHC was measured using digital imaging analysis and was reported in terminal hairs/centimeters square (cm\^2). TAHC is a standardized objective quantification of the number of hairs within a prespecified target area of the scalp at different timepoints, using macrophotography digital images. The total number of terminal hairs (hair width ≥ 30 μm) was calculated from macrophotographs. The target area used to count TAHC was a 1 cm\^2 circular area of clipped hair (length approximately 1 mm) located at the anterior leading edge of the vertex thinning area of the scalp and centered with a semi-permanent microdot tattoo to ensure the same target area was reproduced at each visit. A positive change from Baseline indicated improvement (increase in the number of terminal hairs). Missing data are imputed up to Week 24 using last observation carried forward (LOCF) method.
Subject Self-Assessment (SSA) Score in Hair Growth at Week 24Week 24The SSA consisted of a single-item measure that assesses each participant's perception of change in scalp hair growth. The participant used a standardized global photograph of his scalp taken at the Screening visit presented side by side with a standardized global photograph taken at the postbaseline visit to give a comparative score. The photographs were presented in a blinded and randomized manner to avoid influencing the participant, and response options were on a 7-point ordinal scale (where, -3=Greatly decreased, -2=Moderately decreased, -1=Slightly decreased, 0=No change, +1=Slightly increased, +2=Moderately increased and +3=Greatly increased). The higher the mean SSA value, the more the perception of hair growth from baseline. Missing data are imputed up to Week 24 using LOCF method.

Countries

United States

Participant flow

Participants by arm

ArmCount
Placebo
Two placebo tablets BID at 12-hour intervals for 24 weeks.
70
Setipiprant
Setipiprant 1000 mg (2 X 500 mg) tablets, orally, BID at 12-hour intervals for 24 weeks.
78
Finasteride
Finasteride 1 mg tablet, orally, once daily for 24 weeks.
11
Total159

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyAdverse Event261
Overall StudyLost to Follow-up1181
Overall StudyNon-Compliance with Study Drug200
Overall StudyWithdrawal of Consent11122

Baseline characteristics

CharacteristicPlaceboSetipiprantFinasterideTotal
Age, Continuous36.9 years
STANDARD_DEVIATION 6.08
36.3 years
STANDARD_DEVIATION 6.69
34.1 years
STANDARD_DEVIATION 3.05
36.4 years
STANDARD_DEVIATION 6.25
Race/Ethnicity, Customized
American Indian or Alaska Native
0 Participants0 Participants1 Participants1 Participants
Race/Ethnicity, Customized
Asian
4 Participants1 Participants1 Participants6 Participants
Race/Ethnicity, Customized
Black or African American
4 Participants3 Participants0 Participants7 Participants
Race/Ethnicity, Customized
Hispanic
6 Participants8 Participants0 Participants14 Participants
Race/Ethnicity, Customized
Missing
0 Participants1 Participants0 Participants1 Participants
Race/Ethnicity, Customized
Native Hawaiian or Other Pacific Islander
2 Participants1 Participants0 Participants3 Participants
Race/Ethnicity, Customized
Non-hispanic
64 Participants70 Participants11 Participants145 Participants
Race/Ethnicity, Customized
Other
1 Participants2 Participants0 Participants3 Participants
Race/Ethnicity, Customized
White
59 Participants70 Participants9 Participants138 Participants
Sex/Gender, Customized
Male
70 Participants78 Participants11 Participants159 Participants
Target Area Hair Count (TAHC) Within Left 1 cm^2 Circular Area136.7 terminal hairs/cm^2
STANDARD_DEVIATION 55.81
148.6 terminal hairs/cm^2
STANDARD_DEVIATION 64.58
139.9 terminal hairs/cm^2
STANDARD_DEVIATION 47.72
142.8 terminal hairs/cm^2
STANDARD_DEVIATION 59.67

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 730 / 810 / 12
other
Total, other adverse events
26 / 7328 / 816 / 12
serious
Total, serious adverse events
2 / 730 / 810 / 12

Outcome results

Primary

Change From Baseline in Target Area Hair Count (TAHC) at Week 24

TAHC was measured using digital imaging analysis and was reported in terminal hairs/centimeters square (cm\^2). TAHC is a standardized objective quantification of the number of hairs within a prespecified target area of the scalp at different timepoints, using macrophotography digital images. The total number of terminal hairs (hair width ≥ 30 μm) was calculated from macrophotographs. The target area used to count TAHC was a 1 cm\^2 circular area of clipped hair (length approximately 1 mm) located at the anterior leading edge of the vertex thinning area of the scalp and centered with a semi-permanent microdot tattoo to ensure the same target area was reproduced at each visit. A positive change from Baseline indicated improvement (increase in the number of terminal hairs). Missing data are imputed up to Week 24 using last observation carried forward (LOCF) method.

Time frame: Baseline (Day 1) to Week 24

Population: mITT population included all randomized participants who received study intervention and had a baseline and at least 1 postbaseline measurement for 1 of the coprimary efficacy measures. As per protocol Amendment 1, Finasteride arm group was not included in the analysis model. Number analyzed is participants with data available for analysis.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboChange From Baseline in Target Area Hair Count (TAHC) at Week 246.7 terminal hairs/cm^2Standard Error 3.25
SetipiprantChange From Baseline in Target Area Hair Count (TAHC) at Week 247.1 terminal hairs/cm^2Standard Error 3.03
p-value: 0.923995% CI: [-8.38, 9.23]ANCOVA
Primary

Subject Self-Assessment (SSA) Score in Hair Growth at Week 24

The SSA consisted of a single-item measure that assesses each participant's perception of change in scalp hair growth. The participant used a standardized global photograph of his scalp taken at the Screening visit presented side by side with a standardized global photograph taken at the postbaseline visit to give a comparative score. The photographs were presented in a blinded and randomized manner to avoid influencing the participant, and response options were on a 7-point ordinal scale (where, -3=Greatly decreased, -2=Moderately decreased, -1=Slightly decreased, 0=No change, +1=Slightly increased, +2=Moderately increased and +3=Greatly increased). The higher the mean SSA value, the more the perception of hair growth from baseline. Missing data are imputed up to Week 24 using LOCF method.

Time frame: Week 24

Population: mITT population included all randomized participants who received study intervention and had a baseline and at least 1 postbaseline measurement for 1 of the coprimary efficacy measures. As per protocol Amendment 1, Finasteride arm group was not included in the analysis model. Number analyzed is participants with data available for analysis.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboSubject Self-Assessment (SSA) Score in Hair Growth at Week 24-0.2 score on a scaleStandard Error 0.15
SetipiprantSubject Self-Assessment (SSA) Score in Hair Growth at Week 24-0.3 score on a scaleStandard Error 0.14
p-value: 0.910195% CI: [-0.42, 0.37]ANCOVA

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026